{"disease":{"id":"androgen-insensitive-prostatic-cancer","name":"androgen insensitive prostatic cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05551117","title":"A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":192,"lead_sponsor_name":"MacroGenics","has_results":true},{"nct_id":"NCT05848011","title":"A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"MacroGenics","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}